Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

797 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
Usmani SZ, Hoering A, Ailawadhi S, Sexton R, Lipe B, Hita SF, Valent J, Rosenzweig M, Zonder JA, Dhodapkar M, Callander N, Zimmerman T, Voorhees PM, Durie B, Rajkumar SV, Richardson PG, Orlowski RZ; SWOG1211 Trial Investigators. Usmani SZ, et al. Among authors: rajkumar sv. Lancet Haematol. 2021 Jan;8(1):e45-e54. doi: 10.1016/S2352-3026(20)30354-9. Epub 2020 Dec 22. Lancet Haematol. 2021. PMID: 33357482 Free PMC article. Clinical Trial.
Current therapy for multiple myeloma.
Rajkumar SV, Gertz MA, Kyle RA, Greipp PR; Mayo Clinic Myeloma, Amyloid, and Dysproteinemia Group. Rajkumar SV, et al. Mayo Clin Proc. 2002 Aug;77(8):813-22. doi: 10.4065/77.8.813. Mayo Clin Proc. 2002. PMID: 12173715 Review.
Bone marrow angiogenesis in multiple myeloma: effect of therapy.
Kumar S, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV. Kumar S, et al. Among authors: rajkumar sv. Br J Haematol. 2002 Dec;119(3):665-71. doi: 10.1046/j.1365-2141.2002.03871.x. Br J Haematol. 2002. PMID: 12437642 Free article.
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. Richardson PG, et al. Among authors: rajkumar sv. N Engl J Med. 2003 Jun 26;348(26):2609-17. doi: 10.1056/NEJMoa030288. N Engl J Med. 2003. PMID: 12826635 Free article. Clinical Trial.
Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma.
Thompson MA, Witzig TE, Kumar S, Timm MM, Haug J, Fonseca R, Greipp PR, Lust JA, Rajkumar SV. Thompson MA, et al. Among authors: rajkumar sv. Br J Haematol. 2003 Oct;123(2):305-8. doi: 10.1046/j.1365-2141.2003.04605.x. Br J Haematol. 2003. PMID: 14531913 Free article. Clinical Trial.
Clinical course of patients with relapsed multiple myeloma.
Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Witzig TE, Lust JA, Larson DR, Kyle RA, Greipp PR. Kumar SK, et al. Among authors: rajkumar sv. Mayo Clin Proc. 2004 Jul;79(7):867-74. doi: 10.4065/79.7.867. Mayo Clin Proc. 2004. PMID: 15244382
797 results